Galenica becoming Vifor after Santé spinout

The Galenica Group spun out its pharmacy and consumer healthcare business into Galenica Santé (SIX:GALE) via an IPO on the SIX Swiss Exchange. The remaining Galenica Group business is to be renamed Vifor Pharma Group (SIX:VIFN), and will focus on iron deficiency, nephrology and cardio-renal therapies.

Vifor's subsidiaries will include hyperkalemia play Relypsa Inc., which Galenica acquired in September 2016. Last year, Galenica said the buyout would strengthen Vifor's U.S. commercial presence ahead of the split. Its name and ticker changes will be effective next month (see BioCentury Extra, July 21, 2016)...